Patient-derived scaffolds - a model for identifying cancer promoting properties of the tumor microenvironment relevant for cancer drug design and treatment prediction
Accelerating the drug development process with Bruker high-throughput mass spec solutions powered by timsTOF technology and Bruker SPR Pro: Multiple ways of kinetic profiling with High Throughput Surface Plasmon Resonance
Artificial intelligence in drug discovery: combining clinical and genomic data from cancer patients to identify genetic biomarkers and potential novel targets
High Throughout Mass Spectrometry (HTMS), combining Acoustic Ejection MS Innovation and Efficient Assay Development & Screening Capabilities to Accelerate Drug Discovery